.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,942,519

« Back to Dashboard

Claims for Patent: 5,942,519

Title: Prevention of precipitated acute urinary retention
Abstract:This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5.alpha.-reductase to the subject. The present invention also provides for a method of reducing the risk of precipitated acute urinary retention by the administration of a 5.alpha.-reductase inhibitor to the subject at risk therefor.
Inventor(s): Waldstreicher; Joanne (Scotch Plains, NJ)
Assignee: Merck & Co., Inc. (Rahway, NJ)
Application Number:09/178,138
Patent Claims: 1. A method for reducing the risk of precipitated acute urinary retention in a male subject at risk therefor, comprising administration of an effective amount of an inhibitor of 5.alpha.-reductase to the subject.

2. A method for reducing the risk of precipitated acute urinary retention in a male subject at risk therefor, comprising administration of a compound of structural formula I to the subject: ##STR5## wherein R is selected from: (a) C.sub.1-10 alkyl, unsubstituted or substituted with one to three halogen substituents, and

(b) phenyl, unsubstituted or substituted with one to three substituents independently selected from halogen, methyl, and trifluoromethyl;

or a pharmaceutically acceptable solvate or crystal form thereof.

3. The method of reducing the risk of precipitated acute urinary retention according to claim 2, wherein R is selected from:

(a) unsubstituted C.sub.1-10 alkyl, and

(b) phenyl unsubstituted or substituted with one or two trifluoromethyl substituents.

4. The method of reducing the risk of precipitated acute urinary retention according to claim 2, wherein R is t-butyl.

5. The method of reducing the risk of precipitated acute urinary retention according to claim 2, wherein R is 2,5-bis(trifluoromethyl )phenyl.

6. The method according to claim 1, wherein the precipitated acute urinary retention is precipitated by anesthesia or surgery; a precipitating medical event; a precipitating medical condition such as prostatitis or urinary tract infection; or ingestion of medication known to precipitate retention.

7. The method according to claim 6, wherein the precipitating medical event is selected from stroke and congestive heart failure; the precipitating medical condition is selected from prostatitis and urinary tract infection; and the medication known to precipitate retention is selected from pseudoephedrine hydrochloride, cold medicine, narcotics, sedatives, and benadryl.

8. The method according to claim 6, wherein the precipitated acute urinary retention is precipitated by anesthesia or surgery.

9. The method according to claim 1 for reducing the risk precipitated acute urinary retention in a subject at risk therefor, comprising administration of finasteride at a dose of 5 mg per day.

10. A method of preventing precipitated acute urinary retention in a male subject susceptible thereto, comprising administration of an effective amount of an inhibitor of 5.alpha.-reductase to the subject.

11. A method of preventing precipitated acute urinary retention in a male subject susceptible thereto, comprising administration of a compound of structural formula I to the subject: ##STR6## wherein R is selected from: (a) C.sub.1-10 alkyl, unsubstituted or substituted with one to three halogen substituents, and

(b) phenyl, unsubstituted or substituted with one to three substituents independently selected from halogen, methyl, and trifluoromethyl;

or a pharmaceutically acceptable solvate or crystal form thereof.

12. The method of preventing precipitated acute urinary retention according to claim 11, wherein R is selected from:

(a) unsubstituted C.sub.1-10 alkyl, and

(b) phenyl unsubstituted or substituted with one or two trifluoromethyl substituents.

13. The method of preventing precipitated acute urinary retention according to claim 11, wherein R is t-butyl.

14. The method of preventing precipitated acute urinary retention according to claim 11, wherein R is 2,5-bis(trifluoromethyl)phenyl.

15. The method according to claim 10, wherein the precipitated acute urinary retention is precipitated by anesthesia or surgery; a precipitating medical event; a precipitating medical condition; or ingestion of medication known to precipitate retention.

16. The method according to claim 15, wherein the precipitating medical event is selected from stroke and congestive heart failure; the precipitating medical condition is selected from prostatitis and urinary tract infection; and the medication known to precipitate retention is selected from pseudoephedrine hydrochloride, cold medicine, narcotics, sedatives, and benadryl.

17. The method according to claim 15, wherein the precipitated acute urinary retention is precipitated by anesthesia.

18. The method according to claim 10 preventing precipitated acute urinary retention in a subject susceptible thereto, comprising administration of finasteride at a dose of 5 mg per day.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc